Alteogen Inc.
196170
Rank in Stocks
#1844
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters,... ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial; and Biogen Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
Share Price
$165.61
Market Cap
$11.53B
Change (1 day)
4.13%
Change (1 year)
-46.48%
Country
KR
Trade Alteogen Inc. (196170)
Category
Healthcare
P/E ratio for Alteogen Inc. (196170)
P/E ratio as of October 2026 TTM: 66.81
According to Alteogen Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 66.81. At the end of 2023 the company had a P/E ratio of -1.40K.
P/E ratio history for Alteogen Inc. from 2012 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 66.81 | -74.70% |
| 2024 | 264.07 | -118.84% |
| 2023 | -1.40K | 462.34% |
| 2022 | -249.30 | -59.17% |
| 2021 | -610.60 | 91.95% |
| 2020 | -318.10 | -74.97% |
| 2019 | -1.27K | 2,138.05% |
| 2018 | -56.79 | 45.50% |
| 2017 | -39.03 | -28.01% |
| 2016 | -54.22 | -128.12% |
| 2015 | 192.83 | 63.31% |
| 2014 | 118.08 | 232.26% |
| 2013 | 35.54 | 2.71% |
| 2012 | 34.60 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 28.78 | -56.92% |
US
|
|
| -28.36 | -142.45% |
US
|
|
| -24.57 | -136.77% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -54.60% |
NL
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.